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ABSTRACT 
Introduction: Psoriasis is a dynamic, genetic, immunological, systemic disorder manifesting on the body surface as well as in the joints in a significant 
proportion of patients. Psoriasis affects both sexes equally and can occur at any age. The pathogenesis involves a complex system of mixture of many 
factors like environmental, chemical, genetic and immunological factors. Many treatment options were available and our objective is to find out which 
of the two oral therapies are better from therapeutic outcomes point of view i.e. 75% improvement in PASI score.  Materials and methods: PASI score 
sheets, patients with moderate to severe forms of psoriasis were included in the study and were assigned to either methotrexate or acitretin treatment 
group. The study was randomized controlled study and was conducted for a period of 8 months. Results: A total of 30 patients were inducted into the 
study (N=30), males were 15 and females were 15. For psoriasis vulgaris, acitretin took 6.07 weeks to achieve 75% improvement in PASI score whereas 
Methotrexate took 7.9 weeks. For Plantar psoriasis, acitretin took 5.95 weeks whereas methotrexate took 9.47 weeks. For palmoplantar psoriasis, 
acitretin took 8.32 weeks and for palmar psoriasis, acitretin took 3.4 weeks. For plaque psoriasis, acitretin took 5 weeks, whereas methotrexate took 8.5 
weeks to achieve 75% improvement in PASI score. Conclusion: Although Acitretin appears to be more efficient than MTX in terms of number of days 
required to achieve 75% improvement in PASI score and ADRs, actually MTX is more effective than Acitretin if the frequency of dose or number of doses 
is compared.  
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INTRODUCTION 
Psoriasis has traditionally been considered an inflammatory 
skin disorder of unknown etiology producing red, scaly patches of mere 
cosmetic nuisance to patients. But, with recent knowledge gleamed from 
the immuno-pathogenesis and genetics of psoriasis together with what 
may be termed the biological revolution in therapy, psoriasis now has to 
be considered a dynamic, genetic, immunological, systemic disorder 
manifesting on the body surface as well as in the joints in a significant 
proportion of patients. Now it is the time to consider psoriasis as a 
condition no different from other immune-mediated disorders such as 
Crohn’s disease, Rheumatoid Arthritis, and Lupus Erythematosus, all of 
which have a vast range of clinical manifestations [1]. The Committee on 
Guidelines of Care and the Taskforce on Psoriasis of the American 
Academy of Dermatology defines psoriasis as “A chronic skin disease 
that is classically characterized by thickened, red areas of skin covered 
with silvery scales” [2]. The extent of skin involvement can range from 
discrete, localized areas to generalized body involvement. The joints, 
nails, and mucous membranes may also be affected with the disease. 
Psoriasis may be symptomatic throughout one’s lifetime, may progress 
with age, or may wax and wane in severity [3]. The most frequently  
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experienced psoriasis symptoms include- Scaling, Itching, Skin redness, 
Skin tightness, Bleeding, Burning sensation & Fatigue [4]. Psoriasis has 
traditionally been classified purely on the basis of body surface area 
involvement: 
 Mild psoriasis corresponds to less than 5% of body surface area 
involvement, 
 Moderate corresponds to 5-15% of body surface area 
involvement,& 
 Severe psoriasis, over 15-20% of body surface area 
involvement. 
Psoriasis can be classified according to morphological 
variants as follows - Discoid plaque, Elephantine, Erythrodermic, 
Flexural, Guttate, Palmar-plantar, Pustular - (Localized and 
Generalized), Nail psoriasis, Psoriatic arthritis [5]. The cause of psoriasis 
is unknown. There are various hypotheses proposed of etiological 
factors, which are---- 
 Defects in epidermal cell cycle 
 Disruption in arachidonic acid metabolism 
 Genetics 





Drugs (Corticosteroids, Lithium, antimalarials, beta-blockers, 
ACE inhibitors, etc.) 
 Immunologic mechanisms. 
There are various treatment options available for psoriasis 
which may be termed as psoriasis treatment ladder which is as follows. 
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Psoriasis treatment ladder: [Lebwohl M et al 1995; Abel EA 1995; 
Greaves MW et al 1995] 
 The topical treatment of psoriasis is first-line and mainstream 
in the US as well as in India. Topical agents are generally considered to 
be easy to administer, cost-effective, safe, and acceptable to patients. 
They are typically prescribed as the initial treatment when plaque 
psoriasis affects less than 20% of the body surface. But, for patients with 
moderate to severe disease, topical agents may not be appropriate or 
acceptable. Application to a large body surface area is time-consuming, 
expensive, and puts the patient at increased risk for systemic adverse 
effects. Cutaneous side effects may be intolerable over a large area. 
Topical agents can be messy and may look or feel unacceptable to the 
patient. Using quality-of-life parameters, response to treatment has 
been used to define severity; by this definition severe psoriasis does not 
have a satisfactory response to treatments that have minimal risks [6]. In 
treating patients with a chronic disease such as psoriasis, treatment 
effectiveness, duration of effectiveness, and safety are integral 
components of a treatment plan. Topical steroids may have good short-
term effects but long-term lesion clearance is far from satisfactory. By 
including both the quality and duration of improvement criteria, it was 
perceived that photo/systemic treatments work better than topical 
steroids. In a report, an analysis of multiple studies on the effectiveness 
of these therapies was performed. This report quantitates the clearance 
rates of available treatments and was concluded that the available 
topical forms of therapy are not yet as effective for psoriasis, lesion for 
lesion, as the photo/systemic modalities [7]. Systemic therapy usually 
refers to the drugs or biologicals that are administered orally without 
any exposure to UV radiation. But there is systemic PUVA therapy in 
which the patient is given methoxsalen orally and is subsequently 
exposed to an indoor artificial ultraviolet A radiation within the range of 
302-400 nm. The methoxsalen is a photosensitizer, i.e., photon 
absorbing agent, that is found in plants. This PUVA has got severe side 
effects and results in non-compliance wherein the rate is too high. In 
India the frequently used systemic therapies are Acitretin and MTX. 
MTX is indicated for the treatment of patients with moderate to severe 
psoriasis unresponsive to topical therapy. The other conditions are - 
1. Patients with moderate to extensive plaque lesions 
2. Erythrodermic psoriasis 
3. Pustular psoriasis (acute & localized) 
4. Psoriatic arthritis 
5. Extensive psoriasis unresponsive to less toxic therapies 
6. Psoriasis that significantly affects a patient’s economic or 
psychological well-being 
7. Lack of response to phototherapy, PUVA, or retinoids. 
 MTX blocks the synthesis of DNA by inhibiting dihydrofolic 
reductase, preventing the donation of methyl groups during synthesis of 
purine and pyrimidine nucleotides and, particularly, thymidylate [8] . 
Thymidylate, one of the four DNA precursors, is necessary for DNA 
synthesis and the cell division that follows within hours. MTX may exert 
a therapeutic effect in psoriasis by directly interfering with epidermal 
cell proliferation. Psoriatic skin contains twice as many proliferating 
cells and eight times as many cells in the S( synthesis ) phase of cell 
division as normal skin. In addition, the proliferating cells have a cell 
cycle of 36 h, which is eight times faster than normal [9]. Also after 
systemic or intralesional administration MTX inhibits DNA synthesis in 
psoriatic epidermal cells followed within several hours by the cessation 
of mitoses [10]. MTX also have a major immuno-suppressing effect on 
psoriatic disease at levels that do not appear to produce a clinically 
immuno-suppressing side effect profile in patients. This immuno-
suppressing effect of MTX is exhibited by inhibiting both the 
lymphocytes and keratinocytes. MTX is administered for psoriasis 
principally by two schedules: The triple-dose regimen or a single weekly 
dose, either orally or intramuscularly. A majority of dermatologists use 
the triple-dose schedule [11]. 
 Acitretin is the principal active metabolite of the prodrug 
etretinate. They are very similar, except that etretinate is the ethyl ester 
form of acitretin. Under physiological conditions, etretinate is in an 
uncharged state and is 50 times more lipophilic than acitretin, which 
carries a negative charge [12]. Acitretin is a second-generation retinoid, 
one of a group of natural and synthetic analogues of vitamin A that 
control cell differentiation and proliferation in a number of epithelial 
tissues [13]. Retinoids elicit their biological effects by activating nuclear 
receptors and regulating gene transcription [14-16]. The exact molecular 
mechanism by which retinoids are able to exert their effects on psoriasis 
is unknown. It has been demonstrated that acitretin modulates the 
cellular differentiation of the epidermis, which results in decreased 
scaling, erythema and thickness of the plaques. There is also histological 
evidence that acitretin decreases the thickness of the stratum corneum 
and the inflammation in the epidermis associated with psoriasis [17]. The 
usual dose of acitretin is 10-25 mg/day , when being used as 
monotherapy. But there are reports suggesting a daily dose of 75 
mg/day for a rapid response. In pustular psoriasis, 25 mg/day is 
required. A rapid resolution of generalised pustular psoriasis is 
achieved within 10 days of initiating acitretin. After the clearance of 
postulation, the dose may be tapered down to the lowest effective dose { 
e.g., from 25 mg/day to 25 mg every other day or to 10 mg/day}. In 
exfoliative erythrodermic psoriasis, a sequential therapy using 
cyclosporine and acitretin is recommended [18].  
 
MATERIALS AND METHODS 
The study was conducted at two separate dermatology 
clinics in Guntur of Andhra Pradesh, namely “Hanuma Skin Center” run 
by Dr. Shri K.A. Seetharam MD AIIMS New Delhi, and “Dr. Raja Ram 
Memorial Skin Clinic” run by Dr. Smt A. Kavitha MD. About 150-200 
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patients visit these clinics every day and these clinics have attached Bio-
analysis labs and Dispensaries.  
Study Design: Randomised Controlled Trial.   
Study subjects: Patients diagnosed for moderate and severe form of 
psoriasis of types Plaque, Pustular, Palmo-plantar pustulosis etc. 
Patients with mild form of psoriasis who had not responded to topical 
treatments were also considered for inclusion in the study.  Patients of 
ages below 18 years were excluded from the study.   
Patient screening and enrolment:  Diagnosis was made on the basis of 
appearance of plaques, itching, thickness, erythema, and scaling. 
Differential diagnosis was done in order to rule out the occurrence of 
other types of skin diseases which resemble psoriasis, like seborrhoeic 
dermatitis, chronic eczematous dermatitis etc. 
Patients fulfilling the inclusion and exclusion criteria were 
eligible for inclusion and were counseled on the disease and the 
treatment and were then explained about the purpose of the study.  
Patients were also provided information sheet and were requested to 
inform about their consent to participate on the next day.  Consenting 
patients who signed the written informed consent form were assigned 
to one of the two treatment arms, viz., Acetretin arm and Methotrexate 
arm, using a simple randomization technique. 
Study period:  The total study period was for 8 months, which included 
induction period as well as follow-up period.   
Dosage schedule:  For patients inducted into the MTX arm, triple-dose 
schedule was followed wherein 2.5 mg of  MTX under the brand name 
NEOTREXATE or ONCOTREX was administered orally every 12 h for 
three doses (1/1/1), totaling 7.5 mg for the week. One week later, if 
there are no adverse effects, the dosage is increased by one 2.5 mg i.e., a 
total dosage of 10 mg per week (2/1/1). 
For patients inducted into the ACITRETIN arm, a daily dose of 
25 mg/day was administered under the brand name ACITRIN. 
Also some of the patients (with severe plaques) in both the 
groups were given topical therapy concomitantly with the agent into 
whom they are inducted into. This was done only if the concerned 
dermatologist thought that it was appropriate to use topical therapy 
also in those patients. In topical therapy, the agents used were either 
betamethasone+ salicylic acid or emollients. 
Outcome measures: The treatment success was measured by 
estimating the percentage of patients who achieved 75% improvement 
in PASI score from that recorded on baseline date. Also the number of 
days taken by the therapeutic agent to achieve PASI 75 was noted down 
and was also taken as one of the outcome measures. 
Outcome measuring Techniques: The outcome measures were 
recorded by using the following techniques: 
 PASI score sheet with pictograms {annexure 4& 5} 
 Visual Analogues {photographs of body areas affected, from  
baseline date to the date on which PASI 75 was achieved} 
 Patient data documentation form {annexure 3, which contained all 
the information about the patient and also the date of baseline or 
enrollment date}  
 
SOP FORMAT        ANNEXURE - 1 
VERSION – 001/2006 
 
A Comparative study on two systemic therapeutic regimens on psoriasis treatment outcomes 
TABLE OF CONTENTS 
 
S. No. Patients Name with Pasi  score File No. Date of Enrolment Therapeutic Wing Assigned  
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
 
 
SOP FORMAT        ANNEXURE - 2 
VERSION – 001/2006 
PATIENT CONSENT FORM 
 
Name of the Patient………………………………………………………………….. 
Name of the Investigator………………………………………………………….. 
Name of the Institution……………………………………………………………..  
Name of the Research Coordinator(s)………………………………………….. 
For the Patient 
I ……………………………………………………………. exercising my free power of choice, hereby give my consent to be included as a subject in the  
clinical study “A Comparative study on two Conventional systemic Therapeutic regimens on Psoriasis treatment Outcomes”.  
I agree to the following. 
 I understand that I will not be given any new study medication for participation in the study. 
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 I understand that, since I am a psoriatic patient,I become eligible to be included in the study and will be allocated to any one of the study 
regimen.   
 I also understand that if I consent I will be photographed(body parts that are affected by psoriasis)frequently during the course of the study 
and also during the follow up sessions. 
 I understand that the photographs thus taken will be useful in evaluating the pasi score as the treatment goes on as well as the photographs 
act as permanent records of the treatment as well as visual witnesses of the therapeutic outcomes.  
 Also I understand that based on these photographs pasi score can be calculated and thus optimizing the drug dosing will be decided by the 
doctor. 
 I have been informed to my satisfaction by the attending physician about the purpose of the clinical study and study procedures including 
the investigations to monitor and safeguard my body functions. 
 I have been given a full explanation by the supervising doctor of the nature, purpose likely duration of the study and about what I will be 
expected to do. I have fully understood the information sheet given to me. 
 I have been informed that it is my RIGHT to question the attending doctor on all the aspects of the study and I have understood the above 
information as a result. 
 I have not taken part in any investigational study for the past one month. 
 I am also aware of my right to opt out of the study at any time without giving any reason for doing so.  
 I hereby give permission for the doctors in charge of this study to release the information regarding or obtained as a result  of the 
participation in the study to Mr. Anup Jagarlamudi. I understand that medical records that reveal my identity will be kept confidential 
except that they will be provided as noted above or as may be required by law. 
 
Signature of the patient* with date………………………………………………………  
Signature of the impartial witness* with date………………………………………  
 
I confirm that I have explained the nature, purpose and possible hazards of the above study to ………………………………………………………………  
 
Signature of the Investigator with date………………………………………………..  
 
* Signature of the impartial witness is required only if the patient is illiterate : impartial witness will ensure that the patient infor mation sheet and 
patient consent form were explained to the patient in a language understood by the patient. 
 
Name and address of the impartial witness………………………………………. 
 
  
SOPFORMAT        ANNEXURE - 3 
VERSION- 001/2006 
INFORMATION TO THE PATIENTS 
 
A Comparative study on Two Conventional Systemic Therapeutic Regimen on Psoriasis Treatment Outcomes.  
 
Purpose of the study and benefits: 
The proposed clinical research study in which you participate willingly is an open prospective comparative study in which you will be assigned 
randomly to any one of the two treatment arms, viz. 
 
1. Methotrexate or 
2. Acitretin, which are the standard modes of treating psoriasis systemically. 
 
Upon your enrollment in the study, initially you will be required to undergo the standard diagnosing session and you will be assessed by the 
Doctor about the severity of the disease condition by using PASI SCORE SHEET. Then you will be photographed and will be assig ned to any one of the 
above said therapeutic regimen randomly. 
As the therapeutic regimens in dermatology are usually long term processes, you will be required to visit the Doctor as and when  it is 
necessary to attend the follow up sessions. In due course of the treatment (study) , you will be photographed frequently and these photographs will be 
used as visual documents or as visual witnesses of the therapeutic out comes. No photograph will be displayed without your prior consent Also 
frequent photographing of the subject and PASI SCORE calculating will enable the Doctor to evaluate the therapeutic outcomes and subsequently the 
Doctor will be able to optimize the doses and their frequency as needed. 
About PASI, it is a standard tool used globally both,by Physicians or Dermatologists and by patients themselves to evaluate the severity of 
the disease. When the patient uses PASI himself to evaluate the severity of the disease, it is termed as SAPASI, which in its full form stands for self-
administered psoriasis area and severity index. The various parameters used to calculate PASI are - intensity of redness,of the area affected 
(erethyma), degree of thickness, intensity of scaling, and the intensity of the plaque affecting the area. Psoriasis can affect any part of the body, even 
nails. The intensity of various parameters will be measured with a scale ranging from 0 to 4 where in a value of 0 indicates no symptoms, a value of 1 
indicates a slight degree of severity, a value 2 indicates moderate degree of severity, a value of 3 indicates marked degree of severity and a value of 4 
indicates a very marked degree of severity of the disease. The surface involved is also measured by using a scale ranging fro m 1 to 6 where in a value 
of 1 indicates <10% of surface involvement, a value of 2 indicates 10%-29% of surface involvement, a value of 3 indicates 30%-49% of surface 
involventant, a value of 4 indicates 50%-69% of surface involvement, a value of 5 indicates 70%-89% of surface involvement, a value of 6 indicates 
90%-100% of the surface involvement Thus by giving a specific number to a parameter or to the surface, involved, the Doctor will be able to calculate 
the PASI SCORE as 25% or 80% depending on the severity of the disease. 
Possible Risks: 
As the study is a comparative study involving the standard treatment regimens which are being used globally for ages for treating psoriasis, 
them are no study risks involved in the study. There are no new drugs involved in the study, as all the drugs involved in the study are being used by 
Dermatologists worldwide for ages, their safety and possible toxicity or adverse reactions are well known and wall documented. The study will be 
conducted in the same way as the normal standard therapeutic regimen is followed. In exact phrase, there will be no difference between the study and 
the normal course of the treatment. The only difference is that the data collected from the therapeutic regimens will be used to evaluate their  efficacy 
or outcomes. 
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Study Procedure: 
Allocating the subjects randomly to any one of the therapeutic regimens and collecting the data in the form of photographs and PASI SCORE 
as the treatment goes on and evaluating the outcomes of the treatment.  
Study Participation: 
Your participation in the study is voluntary and you may withdraw from the study at any time without having to give reason. If the study 
appears to be unsuitable to you, it will be stopped. 
Your Responsibilities: 
You should adhere to all prescriptions and precautions advised by your Doctor. You should inform the Doctor about your previo us 
illnesses/medications that you intend to take along with those prescribed by the Doctor. 
Our Liabilities: 
In case of any adverse drug event or undesirable event, we will take responsibility to fully take care of your treatment need s at our own 
cost. 
 
FOR FURTHER QUERIES CONTACT THE FOLLOWING PERSON(S): 
 
Investigators name and address: 
 
Dr.-------------------------------------------------- 
      -------------------------------------------------- 
      -------------------------------------------------- 
      -------------------------------------------------- 
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SOP FORMAT        ANNEXURE - 6 
VERSION – 001/2006 
 
A Comparative study on two systemic therapeutic regimens on psoriasis treatment outcomes 
PATIENT DATA DOCUMENTATION FORM 
 
Patient Demography                  Date of 1st Consultation: 
Patients I.D. : 
 
Sex: Age (Yrs): Weight (kg): Height (cm): 
Body surface area (BSA):  Mosteller’s formula    
 
                                                                                                                       Sqrt { height (cm) x weight(kg) } 
                                                                                                                                                      3600 
 
Patient Personal Profile 
Education: Occupation: Social Habits: Residence 
Illiterate               □ 
High School         □ 
Degree                  □ 
 Smoking                                    □ 
Tobacco use                             □ 
Alcohol consumption            □  
Urban          □ 
Rural            □   
 
5 
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Any Other ailments : (Please Specify) 
 
 
Currently if taking any Medication,  Please Specify. 
 
 
Page 1 0f 2 
 
Family History 
Married   □  Yes     □   No    
Any Other person in Family Suffering from Arthritis or Psoriasis or any other ailments : (Please Specify)  
 
Any increase in severity or scaling or itching with climate changes (Please Specify):  
 
 
   Current Diagnosis  
















Date of next follow up Session:  
ADRs Observed: (Please Specify) 
 
Address of the patient :---------------------------------------------------- 
                                             ----------------------------------------------------- 
                                             ----------------------------------------------------- 
                          ----------------------------------------------------- 
                                    ---------------------------------------------------- 
Phone No. of the Patient:------------------------------------------------- 
Remarks:- 
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SOP FORMAT         ANNEXURE - 8                  
VERSION 001/2006                                                
CONSOLIDATED PASI SCORE SHEET 
 
Follow up session 
number 
Date  PASI score Percentage 
improvement in 
PASI score 
Total number of 
days from base 
line 
Due date for next 
follow up session 
Base line or 
enrollment date 
     
1.      
2.      
3.      
4.      
5.      
6.      
7.      
8.      
9.      
10.      
11.      
12.      
13.      
14.      
 
RESULTS 
A total of 30 patients who attended the dermatology clinics 
and diagnosed as psoriatic patients were inducted into the study. All 
these patients had moderate-to-severe psoriasis of various types. 
Out of 30 patients there were 15 males (50 %) and 15 females 
(50 %) [Table 1]  
Table No. 1: Gender Distribution 
Gender Frequency Percent 
Male 15 50 
Female 15 50 
Total(n) 30 100 
 
Out of the 30 patients, 15 were inducted into MTX group,15 
were inducted into Act group.Table.no.2 
Table No. 2: Group Distribution 
Total(n) MTX group Act group 
30 15 15 
 
Table.No.3 shows the incidence of concomitant diseases in 
these 30 patients.  
Table No. 3: Incidence of concomitant diseases 
Disease type Frequency Percent 
Diabetes 4 13.33 
Hypertension 5 16.66 
Arthritis 3 10 
HIV 1 3.33 
Oral cancer 1 3.33 




Hypo tension 1 3.33 
Cellulites 1 3.33 
Total 18 60.00 
 
The age group for all the patients ranged from 19-75 years. 
The maximum incidence of psoriasis was in the age group between 50-
55 years. 
The incidence of various subclinical types of psoriasis was 
shown in Table No. 4. 
Table No. 4: Clinical sub-types distribution of Psoriasis 
Clinical sub type Frequency Percent 
Psoriasis vulgaris 10 33.33 
Plantar 9 30 
Palmar 1 3.33 
Pustular 1 3.33 
Palmo-plantar 2 6.66 
Plaque 3 10 
Erythro dermic 1 3.33 
Plantar +vulgaris 1 3.33 
Palmoplantar+ nail 2 6.66 
Total 30 100 
 
Out of 30 patients,1 patient experienced nausea and 
abdominal discomfort with oral methotrexate and hence was shifted to 
intra muscular MTX therapy (incidence 6.66%). 2 patients experienced  
abdominal discomfort with cetrizine tablets  and hence were  shifted to 
levo citrizine soft gelatin capsules . 
Table no. 5 compares the efficacy of both Acitretin and MTX in 
the treatment of various clinical types of psoriasis. 
Table No. 5: comparison of efficacy of Acitretin and MTX in terms of 
days to reach 75% improvement 
Psoriatic 
clinical type 
Mean number of days 
taken by Acitretin to 
reach 75% 
improvement 
Mean number of 
days taken by MTX to 
reach 75% 
improvement 
Pso. vulgaris 42.5 (6.07 weeks) 55.33 (7.9 weeks) 
Plantar 41.66 (5.95 weeks) 66.33 (9.47 weeks) 
Palmoplantar 58.25 (8.32 weeks) ------------------- 
Palmar 24 (3.4 weeks) ------------------- 
Plaque 35 (5 weeks) 60 (8.5 weeks) 
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Fig. 1: Comparison of therapeutic efficacies of Acitretin and MTX 
 
CONCLUSION 
Although Acitretin appears to be more efficient than MTX in 
terms of number of days   required to achieve 75% improvement in PASI 
score and ADRs, actually MTX is more   effective than Acitretin if the 
frequency of dose or number of doses is compared.   Low dose MTX is an 
effective therapy for extensive and severe forms of psoriasis if patients 
are selected carefully and monitored regularly with respect to liver and 
bone marrow toxicity. This helps to reduce severe side effects even 
during long-term treatment. Monitoring of therapy intermittently is 
necessary. 
In the concept of Pharmaco-Economics, if we compare 
Acitretin with MTX, MTX outweighs Acitretin. Acitretin costs Rs.60/25 
mg tab i.e. suppose a patient had to use Acitretin for 42 days in 
managing pso.vul., he had to spend 42X60=Rs.2520, which is only for 
the temporary management of psoriasis. On the other hand 2.5 mg of 
MTX costs Rs.5 and the patient requires only 3 doses per week 
i.e.3X5=Rs.15 per week and if he undergoes 8(55 days) weeks of  
management therapy, it will cost him 15X8=Rs.120.  We should always 
remember that there is no universal treatment for psoriasis, and that it 
can only be managed temporarily. In the light of this concept we should 
always remember the principles of Pharmaco-Economics. No psoriatic 
patient will be willing to spend an extra of Rs.2400 only for the 
management of psoriasis temporarily. Thus MTX becomes the drug of 
choice to both the patients as well physician’s altogether. 
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